OverviewSuggest Edit

Phio Pharmaceuticals (formerly RXi Pharmaceuticals) is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid (RNA) interference (RNAi). RNAi therapeutic platform includes two components: Novel RNAi Compounds and Advanced Delivery Technologies. The Company has developed a number of forms of rxRNA compounds. These RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self delivering RNA. The suite of delivery technologies is comprised of delivery vehicles, which could be combined with various rxRNA compounds, as well as sd-rxRNA compounds, which are chemically modified and have the property of entering cells and tissues to effect silencing without the need for any additional delivery vehicle.

TypePublic
Founded2011
HQMarlborough, MA, US
Websitephiopharma.com

Latest Updates

Employees (est.) (Mar 2019)9(-40%)
Revenue (FY, 2019)$21 K(-84%)
Share Price (Jan 2021)$3.1 (+3%)
Cybersecurity ratingBMore

Key People/Management at Phio Pharmaceuticals

Gerrit Dispersyn

Gerrit Dispersyn

President and Chief Executive Officer
James Cardia

James Cardia

VP of Business Operations
Simon Fricker

Simon Fricker

Vp of Research
Caitlin Kontulis

Caitlin Kontulis

VP of Finance and Administration
Show more

Phio Pharmaceuticals Office Locations

Phio Pharmaceuticals has an office in Marlborough
Marlborough, MA, US (HQ)
257 Simarano Dr, Marlborough
Show all (1)

Phio Pharmaceuticals Financials and Metrics

Phio Pharmaceuticals Revenue

Phio Pharmaceuticals's revenue was reported to be $21 k in FY, 2019
USD

Net income (Q2, 2020)

(1.7m)

EBIT (Q2, 2020)

(1.7m)

Market capitalization (20-Jan-2021)

17.8m

Closing stock price (20-Jan-2021)

3.1

Cash (30-Jun-2020)

18.9m

EV

(363.8k)
Phio Pharmaceuticals's current market capitalization is $17.8 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

97.0k399.0k19.0k15.0k138.0k21.0k

General and administrative expense

2.6m3.7m3.2m3.3m3.6m4.0m3.2m4.7m

R&D expense

10.5m17.7m5.7m6.9m5.4m5.4m4.3m4.3m

Operating expense total

13.1m21.3m8.9m10.3m9.0m9.4m7.5m9.0m
Quarterly
USDQ1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

57.0k53.0k225.0k92.0k29.0k10.0k9.0k23.0k58.0k57.0k21.0k

General and administrative expense

751.0k539.0k676.0k977.0k934.0k843.0k850.0k766.0k873.0k804.0k770.0k950.0k885.0k752.0k1.1m1.1m986.0k901.0k774.0k711.0k1.1m913.0k1.1m1.1m890.0k

R&D expense

1.2m1.2m13.8m1.2m1.2m1.5m1.2m1.5m2.1m1.4m1.7m1.3m1.3m1.5m1.3m1.3m1.5m1.4m1.2m838.0k1.1m1.1m1.0m1.2m779.0k

Operating expense total

1.9m1.8m14.4m2.2m2.2m2.3m2.0m2.2m3.0m2.2m2.5m2.3m2.2m2.2m2.5m2.4m2.5m2.3m2.0m1.5m2.2m2.1m2.1m2.4m1.7m
USDQ1, 2012

Financial Leverage

-0.7 x
Show all financial metrics

Phio Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Phio Pharmaceuticals Online and Social Media Presence

Embed Graph

Phio Pharmaceuticals News and Updates

Thinking about buying stock in Immersion Corp, IRIDEX Corp, One Stop Systems, Phio Pharmaceuticals, or Alkermes?

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMR, IRIX, OSS, PHIO, and ALKS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference

MARLBOROUGH, Mass., Nov. 19, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief...

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming...

Phio Pharmaceuticals to Present at Biotech Showcase 2020

MARLBOROUGH, Mass., Jan. 6, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its chief...

Phio Pharmaceuticals and Karolinska Institutet Expand Collaboration to Develop Self-Delivering RNAi Immunotherapies for Treating Solid Tumors

MARLBOROUGH, Mass., Nov. 21, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next-generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it...

Phio Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Nov. 12, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INSTASYL™) therapeutic platform, today reported its financial...
Show more

Phio Pharmaceuticals Frequently Asked Questions

  • When was Phio Pharmaceuticals founded?

    Phio Pharmaceuticals was founded in 2011.

  • Who are Phio Pharmaceuticals key executives?

    Phio Pharmaceuticals's key executives are Gerrit Dispersyn, James Cardia and Simon Fricker.

  • How many employees does Phio Pharmaceuticals have?

    Phio Pharmaceuticals has 9 employees.

  • What is Phio Pharmaceuticals revenue?

    Latest Phio Pharmaceuticals annual revenue is $21 k.

  • What is Phio Pharmaceuticals revenue per employee?

    Latest Phio Pharmaceuticals revenue per employee is $2.3 k.

  • Who are Phio Pharmaceuticals competitors?

    Competitors of Phio Pharmaceuticals include Aimmune Therapeutics, GeoVax and Emisphere Technologies.

  • Where is Phio Pharmaceuticals headquarters?

    Phio Pharmaceuticals headquarters is located at 257 Simarano Dr, Marlborough, Marlborough.

  • Where are Phio Pharmaceuticals offices?

    Phio Pharmaceuticals has an office in Marlborough.

  • How many offices does Phio Pharmaceuticals have?

    Phio Pharmaceuticals has 1 office.